Pharmacytimes: Condition Center: Cardiovascular Health Cardiovascular Health en-us Sun, 19 Feb 2017 06:45:05 UTC Sun, 19 Feb 2017 06:45:05 UTC Can We Have a Statin Appreciation Day? Statins save lives 9:34 PM, Sun February 12, 2017 Child Vaccinations, Smoking Prevention Ranked Highest Among Preventive Services Other highly ranked services included alcohol screening, aspirin therapy for cardiovascular disease prevention, and colorectal cancer screening. 9:23 AM, Thu January 12, 2017 Sodium-Glucose Cotransporter 2 Inhibitors: Possible Role in Cardiology Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging antidiabetic class that offer significant cardiovascular risk reduction. 10:14 AM, Tue January 10, 2017 Aspirin, Omeprazole Combination Treatment Yosprala Approved The FDA recently approved Aralez Pharmaceuticals’ Yosprala, a once-daily, fixed-dose combination of the antiplatelet agent aspirin and the proton pump inhibitor omeprazole. 7:00 AM, Mon September 26, 2016 The Bloody Scales: Weighing the Risks and Benefits of Long-Term Aspirin Overwhelming research confirms aspirin’s net benefit for secondary prevention of cardiovascular (CV) events. However, the latest CV guidelines suggest providers should weigh the risks and benefits of aspirin for primary prevention. 10:18 PM, Mon September 19, 2016 Is Ticagrelor Superior to Clopidogrel in Real-World ACS Patients? Clinical trial data don’t always reflect real-world experience. 11:37 PM, Sun August 14, 2016 3 Common Barriers to Cardiac Medication Adherence Pharmacists can help evaluate and address adherence barriers among patients taking medications for cardiovascular disease. 8:54 AM, Wed May 18, 2016 Cardiovascular Medication Adherence Not Commonly Discussed with Physicians Despite advances in preventative drug therapy, cardiovascular disease remains the leading cause of death in the United States. 4:45 AM, Wed May 18, 2016 New Guidelines for Primary Prevention of Heart Disease with Aspirin The US Preventive Services Task Force has critically evaluated the literature and provided recommendations regarding aspirin use for primary prevention of CVD and CRC. 1:53 AM, Mon May 9, 2016 Entresto Shows Benefit Even in Clinically Stable Heart Failure Patients Novartis’ sacubitril/valsartan (Entresto) is showing promise for heart failure patients with reduced ejection fraction, regardless of background therapy or clinical stability. 7:00 AM, Thu April 14, 2016 Community Pharmacists Can Curb Cardiovascular Disease Risk A community pharmacist intervention program reduced the estimated risk for cardiovascular events by 21% in 3 months. 4:11 AM, Mon April 11, 2016 Early Follow-Up Care After Heart Attack Key to Medication Adherence Patients receiving follow-up care more than 6 weeks after a heart attack are much less likely to stick to their medication regimen. 10:30 PM, Wed March 23, 2016 FDA Rejects New Indication for Zetia and Vytorin Merck has received a complete response letter from the FDA regarding its supplemental new drug applications for ezetimibe and ezetimibe and simvastatin. 7:00 AM, Thu February 18, 2016 Marijuana Use Linked to Lower Metabolic Syndrome Risk Some studies have reported an association between marijuana use and individual metabolic syndrome factors, while others have found no relationship. 5:13 AM, Mon January 25, 2016 7 Simple Steps to Combat Heart Failure Pharmacists may want to steer their patients toward a resource for their cardiovascular health: the Life’s Simple 7 test from the American Heart Association. 9:08 PM, Mon January 18, 2016 ACS Vocabulary: Are Patients Nonresponsive or Resistant to Therapy? Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is a cornerstone acute coronary syndrome treatment to prevent thrombotic events after coronary stent placement. 10:25 PM, Wed December 2, 2015 6 Ways to Prevent Cardiovascular Disease Pharmacists are in a great position to impart valuable heart-related wisdom to their patients. 11:06 PM, Mon November 30, 2015 ACS Patient Nonadherence Factors Pharmacists Should Target Seven in 10 patients report some extent of nonadherence prior to a hospitalization caused by a cardiovascular event such as acute cardiac failure. 12:00 AM, Fri November 6, 2015 Parkinson's Drug Does Not Increase Risk of Cardiovascular Events The FDA has determined that entacapone, a drug used in the treatment of Parkinson's disease, does not increase patients' risk of heart attacks, stroke, or other cardiovascular events. 9:03 PM, Tue October 27, 2015 What Hinders Good Heart Health Among African-Americans? Cardiovascular disease (CVD) is the most common cause of death in America, but the disease rates for African-Americans are especially high. 10:00 PM, Sun October 11, 2015